Rahul Dave is a Neurology physician. OpenAlex indexes 29 publications with 1,140 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8081 Innovation Park Dr Ste 900
Fairfax, VA 220314867
Telephone
571-472-4200Provider last certified this registry record 21 Apr 2023.
Industry payments
34 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- TG Therapeutics, Inc.Program year202549 payments$86,930openpaymentsdata.cms.gov ↗
- EMD Serono, Inc.Program year202529 payments$34,320openpaymentsdata.cms.gov ↗
- Alexion Pharmaceuticals, Inc.Program year202513 payments$13,081openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
50.5%Gabapentinoids12.5%Pregabalin53%Gabapentin48%Part D≥29 patientsSNRI10.7%Duloxetine Hcl30%Venlafaxine Hcl24%Venlafaxine Hcl Er23%Desvenlafaxine Succinate Er23%Part D<11 patients+ 12 more classes in this area
Cancer & immunology
25%CD20-directed Cytolytic Antibody16.1%Kesimpta Pen100%Part D≥23 patientsPyrimidine Synthesis Inhibitor5%Teriflunomide72%Aubagio28%Part D<11 patients+ 3 more classes in this area
Musculoskeletal
16.8%Muscle Relaxant8.9%Methocarbamol100%Part D≥36 patientsgamma-Aminobutyric Acid-ergic Agonist4.8%Baclofen100%Part D≥19 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- EP.06.34 Retrospective Analysis of Genomic Testing and Survival Outcomes in Lung Cancer Patients From Western India
Journal of Thoracic Oncology
2025 - EP.01.08 Lung Cancer in Elderly Patients: Insights From a Community Oncology Setting in Western India
Journal of Thoracic Oncology
2025 - P3.12.05 Patterns of EGFR Mutations and Real-World Experience of Therapeutic Interventions - a Community Oncology Study
Journal of Thoracic Oncology
2025 - EP.12.01 Real-World Data of ROS-1 Positive Nsclcs- Mutational Heterogeneity, Clinical Characteristics and Its Outcomes
Journal of Thoracic Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”